Ampio Pharmaceuticals (AMPE) 10-Q 12 May 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 01, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Registrant Name	Ampio Pharmaceuticals, Inc.
Entity Central Index Key	1,411,906
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	AMPE
Entity Common Stock, Shares Outstanding		57,242,164

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 2,256,341	$ 4,894,834
Trading security Aytu BioScience, Inc. (Note 4)	91,930	122,641
Prepaid expenses and other	475,335	240,890
Prepaid research and development - related party (Note 6)	143,802	143,802
Total current assets	2,967,408	5,402,167
Fixed assets, net (Note 3)	7,693,942	7,980,011
Long-term portion of prepaid research and development - related party (Note 10)	143,801	179,752
Deposits	33,856	33,856
Total assets	10,839,007	13,595,786
Current liabilities
Accounts payable and accrued expenses	765,474	709,294
Accrued compensation	1,304,052	1,365,693
Deferred rent	59,579	59,579
Total current liabilities	2,129,105	2,134,566
Long-term deferred rent	577,180	588,303
Warrant derivative liability	3,112,133	4,238,606
Total liabilities	5,818,418	6,961,475
Commitments and contingencies (Note 6)
Stockholders' equity
Preferred Stock, par value $.0001; 10,000,000 shares authorized; none issued	0	0
Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding - 57,242,164 in 2017 (unaudited) and 57,179,686 in 2016	5,724	5,718
Additional paid-in capital	160,015,804	159,732,194
Advance to stockholder	0	(25,160)
Accumulated deficit	(155,000,939)	(153,078,441)
Total stockholders' equity	5,020,589	6,634,311
Total liabilities and stockholders' equity	$ 10,839,007	$ 13,595,786

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Preferred Stock, par value	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	57,242,164	57,179,686
Common Stock, shares outstanding	57,242,164	57,179,686

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating expenses
Research and development	$ 1,604,386	$ 4,275,577
Research and development - related party (Note 6)	35,951	35,950
General and administrative	1,362,668	2,110,896
Total operating expenses	3,003,005	6,422,423
Other income (expense)
Interest income	3,033	10,154
Derivative gain	1,126,473	0
Unrealized loss on trading security	(30,711)	0
Loss from equity investment in Aytu BioScience, Inc.	0	(352,520)
Total other income (expense)	1,098,795	(342,366)
Net loss	$ (1,904,210)	$ (6,764,789)
Basic and diluted net loss per common share	$ (0.03)	$ (0.13)
Weighted average number of common shares outstanding	57,240,081	52,016,034

Statements of Stockholders_ Equ

Statements of Stockholders’ Equity - 3 months ended Mar. 31, 2017 - USD ($)	Total	Common Stock [Member]	Additional Paid in Capital [Member]	Advance to Stockholder [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2016	$ 6,634,311	$ 5,718	$ 159,732,194	$ (25,160)	$ (153,078,441)
Beginning Balance, shares at Dec. 31, 2016		57,179,686
Common stock issued for services (unaudited)	60,000	$ 6	59,994	0	0
Common stock issued for services (unaudited), shares		62,478
Warrant modification	74,527	$ 0	74,527	0	0
Stock based compensation	130,801	$ 0	130,801	0	0
Stock-based compensation, shares		0
Stock option compensation forfeitures (see Note 1) (unaudited)	0	$ 0	18,288	0	(18,288)
Write-off of advance (unaudited)	25,160	0	0	25,160	0
Net loss	(1,904,210)	0	0	0	(1,904,210)
Ending Balance at Mar. 31, 2017	$ 5,020,589	$ 5,724	$ 160,015,804	$ 0	$ (155,000,939)
Ending Balance, shares at Mar. 31, 2017		57,242,164

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities
Net loss	$ (1,904,210)	$ (6,764,789)
Adjustments to reconcile net loss to net cash used in operating activities
Losses in equity investment in Aytu BioScience, Inc.	0	352,520
Stock-based compensation and warrant modification	205,328	646,529
Depreciation and amortization	303,522	305,533
Write-off of advances from shareholders	25,160	0
Amortization of prepaid research and development - related party (Note 6)	35,951	35,950
Common stock issued for services	60,000	60,000
Derivative gain	(1,126,473)	0
Unrealized loss on trading security	30,711	0
Changes in operating assets and liabilities
Increase in prepaid expenses and other	(234,445)	(72,684)
Increase in accounts payable	56,180	406,505
Decrease in deferred rent	(11,123)	(8,704)
Increase in accrued compensation	(61,641)	155,402
Net cash used in operating activities	(2,621,040)	(4,883,738)
Cash flows used in investing activities
Purchase of fixed assets	(17,453)	0
Net cash used in investing activities	(17,453)	0
Cash flows from financing activities
Net cash provided by financing activities	0	0
Net change in cash and cash equivalents	(2,638,493)	(4,883,738)
Cash and cash equivalents at beginning of period	4,894,834	15,998,392
Cash and cash equivalents at end of period	2,256,341	11,114,654
Non-Cash transactions:
Distribution to stockholders	$ 0	$ 13,018,687

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Note 1—Basis of Presentation These unaudited financial statements represent the financial statements of Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”). These unaudited financial statements should be read in conjunction with Ampio’s Annual Report on Form 10-K for the year ended December 31, 2016, which included all disclosures required by generally accepted accounting principles (“GAAP”). In the opinion of management, these unaudited financial statements contain all adjustments necessary to present fairly the financial position of Ampio for the balance sheet and the results of operations and cash flows for the interim periods presented. The results of operations for the period ended March 31, 2017 are not necessarily indicative of expected operating results for the full year. The information presented throughout this report as of and for the period ended March 31, 2017 is unaudited. Ampio is a biopharmaceutical company focused on primarily developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depleting available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability. Ampio’s activities have been primarily related to research and development and raising capital and have not generated revenue to date. Adoption of Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation –Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting” 18,000 In August 2016, the FASB issued ASU 2016-15 Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, which provides guidance on the presentation of certain cash receipts and cash payments in the statement of cash flows to reduce diversity in existing practice. ASU 2016-15 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted. During fiscal 2016, the Company early adopted this standard with no impact on the quarters ended March 31, 2017 and March 31, 2016 cash flow categorizations. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2—Going Concern As reflected in the accompanying financial statements, the Company had cash of less than $ 2.3 1.9 2.6 5.0 155.0 The Company expects that its current cash resources as well as expected lack of operating cash flows will not be sufficient to sustain operations for a period greater than a few weeks from this Form 10-Q issuance date. The ability of the Company to continue its operations is dependent on management's plans, which include continuing to raise equity-based and debt financing. The Company is currently in negotiation with potential investors for financing. There is no assurance that the Company will be successful in raising sufficient capital. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Fixed Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 3—Fixed Assets Estimated As of March 31, As of December 31, Useful Lives in years 2017 2016 Manufacturing facility/clean room 8 $ 2,734,000 $ 2,734,000 Leasehold improvements 10 6,075,000 6,075,000 Office furniture and equipment 3 -10 557,000 557,000 Lab equipment 5 -10 1,044,000 1,026,000 Less accumulated depreciation and amortization (2,716,000) (2,412,000) Fixed assets, net $ 7,694,000 $ 7,980,000

Trading Security Aytu BioScienc

Trading Security Aytu BioScience, Inc.	3 Months Ended
	Mar. 31, 2017
Investment Disclosure [Abstract]
Investment Disclosure	Note 4—Trading Security Aytu BioScience, Inc. On January 4, 2016, Ampio completed the spin-off of Aytu BioScience, Inc. (“Aytu”) by distributing a majority of its shares of common stock of Aytu to the Ampio shareholders on a pro rata basis. This transaction changed Ampio’s ownership from 81.5 8.6 In May 2016, Aytu completed an offering which was dilutive to the Aytu shares held by Ampio. In the beginning of July 2016, Aytu added a fifth Board member. At that time, the Company determined that Ampio’s influence was no longer significant over Aytu’s Board of Directors. Ampio reclassified its remaining investment in Aytu to a trading security in July of 2016. The Aytu security is recorded at fair value on the accompanying balance sheet with the change in fair value recorded as an unrealized loss on the statement of operations. As of March 31, 2017, Ampio’s ownership in Aytu’s outstanding shares was less than 1.0%.

Fair Value Considerations

Fair Value Considerations	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures	Note 5—Fair Value Considerations The Company’s financial instruments include cash and cash equivalents, trading security in Aytu, accounts payable and accrued expenses, and warrant derivative liability. The valuation policies are determined by the Chief Financial Officer and approved by the Company’s Board of Directors. Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of Ampio. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Ampio for identical assets or liabilities; Level 2: Inputs including quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. Ampio’s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Ampio’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Ampio has consistently applied the valuation techniques discussed below in all periods presented. Fair Value Measurements Using Level 1 Level 2 Level 3 Total March 31, 2017 ASSETS Trading security Aytu (Note 4) $ 92,000 $ - $ - $ 92,000 LIABILITIES Warrant derivative liability $ - $ - $ 3,112,000 $ 3,112,000 December 31, 2016 ASSETS Trading security Aytu (Note 4) $ 123,000 $ - $ - $ 123,000 LIABILITIES Warrant derivative liability $ - $ - $ 4,239,000 $ 4,239,000 The estimated fair value of the Company’s investment, the trading security in Aytu is recorded at fair value which represents Ampio’s ownership shares in Aytu of 102,201 269,000 Value at December 31, Unrealized Fair Value Maturity in Years 2016 Gains Losses 2017 Trading security Aytu (Note 4) Less than 1 year $ 123,000 $ - $ (31,000) $ 92,000 The warrant derivative liability was valued using the Black-Scholes valuation methodology because that model embodies all the relevant assumptions that address the features underlying these instruments. For significant assumptions in valuing the warrant derivative liability as of March 31, 2017 and at issuance (see Note 8). Derivative Instruments Balance as of December 31, 2016 $ 4,239,000 Change in fair value included in derivative gain (1,127,000) Balance as of March 31, 2017 $ 3,112,000

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6—Commitments and Contingencies Remaining Total 2017 2018 2019 2020 2021 Thereafter Ampion supply agreement $ 7,650,000 $ 2,550,000 $ 2,550,000 $ 2,550,000 $ - $ - $ - Clinical research and trial obligations 557,000 557,000 - - - - - Facility lease 2,552,000 231,000 316,000 326,000 335,000 345,000 999,000 Sponsored research agreement with related party 695,000 289,000 325,000 81,000 - - - $ 11,454,000 $ 3,627,000 $ 3,191,000 $ 2,957,000 $ 335,000 $ 345,000 $ 999,000 Ampion Supply Agreement In October 2013, Ampio entered into a human serum albumin ingredient and purchase sale agreement which has a remaining commitment of $ 7.7 Clinical Research and Trial Obligations As of March 31, 2017, Ampio has committed to $ 557,000 Facility Lease On December 13, 2013 125 May 1, 2014 23,000 3.3 Three Months Ended March 31, 2017 2016 Rent expense $ 65,000 $ 73,000 Sponsored Research Agreement with Related Party Ampio entered into a Sponsored Research Agreement with Trauma Research LLC (“TRLLC”), a related party, in September 2009. Under the terms of the Sponsored Research Agreement, Ampio is to provide personnel and pay for leased equipment. The Sponsored Research Agreement may be terminated without cause by either party on 180 264,000 325,000

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Common Stock	Note 7—Common Stock Capital Stock At March 31, 2017 and December 31, 2016, Ampio had 57,242,164 57,179,686 100.0 0.0001 10.0 0.0001 Shelf Registration In December 2013, Ampio filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”) to register Ampio common stock and warrants in an aggregate amount of up to $ 100.0 1.5 82.4 A new Form S-3 was filed with the SEC in March of 2017 to register Ampio common stock, preferred stock, debt securities warrants in an aggregate amount of up to $100 million from time to time and became effective in April of 2017. Until the Company has a market cap of $75.0 million exclusive of stock held by affiliates, the Company may only sell up to $ 18.6 Registered Direct Offering In September 2016, the Company completed a registered direct offering. In this offering, the Company issued directly to an institutional investor 5.0 5.0 0.75 3.75 The investor warrants had an exercise price of $ 1.00 5.0 Distinguishing Liabilities from Equity” 4.1 In connection with the offering the placement agent received a 6 225,000 150,000 0.9375 89,000 113,000 The Company’s net cash proceeds for the registered direct offering were $ 3.4 4.2 5.0 150,000 804,000 On March 27, 2017, the Company entered into a Waiver and Consent Letter Agreement (the “Waiver and Consent Agreement”) with the investor, amending the terms of warrants previously issued to the investor in September 2016. Under the Waiver and Consent Agreement, the investor waived the right to have the warrant exercise price reduced and the number of shares of common stock underlying the warrant increased in the event the Company secures any financing, including debt, which includes issuing or selling shares of common stock for a price per share less than the warrant exercise price. The investor also waived the prohibition on the Company’s ability to issue or sell shares of its common stock, options or convertible securities at a price which varies or may vary with the market price of the common stock or pursuant to an equity credit line or similar “at-the-market” offering. The waivers are permanent. In return, the Company agreed to reduce the exercise price of the warrants from $1.00 to $0.40 and to not issue or sell any shares of its capital stock for a period of 10 trading days following the execution of the Waiver and Consent Agreement. All other terms of the warrants remained the same. Based upon the amendment to this warrant agreement, the company recognized a non-cash derivative gain of $ 1.1 Controlled Equity Offering In February 2016, Ampio entered into a Controlled Equity Offering SM 25.0 3.0 The following table summarizes Ampio’s total sales under the Agreement for the period indicated: Year Ended December 31, 2016 Total shares of common stock sold 163,254 Average price per share $ 0.94 Gross proceeds $ 153,000 Commissions earned by placement agent $ 5,000 Other expenses $ 98,000 No shares were sold under the Agreement in the quarter ended March 31, 2017. Common Stock Issued for Services Ampio issued 62,478 18,126 60,000 60,000

Equity Instruments

Equity Instruments	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Instruments	Note 8—Equity Instruments Options In 2010, Ampio shareholders approved the adoption of a stock and option award plan (the “2010 Plan”), under which shares were reserved for future issuance under restricted stock awards, options, and other equity awards. The 2010 Plan permits grants of equity awards to employees, directors and consultants. The shareholders have approved a total of 11.7 During the three months ended March 31, 2017, the Company granted 585,000 0.85 25,000 560,000 Ampio stock option activity is as follows: Weighted Weighted Average Number of Average Remaining Options Exercise Price Contractual Life Outstanding December 31, 2016 7,175,832 $ 3.64 4.99 Granted 585,000 $ 0.85 Exercised - $ - Forfeited - $ - Expired or Cancelled (3,334) $ 3.02 Outstanding March 31, 2017 7,757,498 $ 3.43 5.13 Exercisable at March 31, 2017 6,904,827 $ 3.71 4.58 Available for grant at March 31, 2017 2,467,503 Number of Weighted Weighted Average Options Average Remaining Range of Exercise Prices Outstanding Exercise Price Contractual Lives $0.81 - $2.00 2,575,554 $ 1.06 5.22 $2.01 - $5.00 3,111,944 $ 3.06 5.00 $5.01 - $8.93 2,070,000 $ 6.94 5.21 7,757,498 $ 3.43 5.13 Ampio has computed the fair value of all options granted using the Black-Scholes option pricing model. To calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Ampio calculates its volatility assumption using the actual changes in the market value of our stock. Ampio adopted ASU 2016-09 in 2017 and no longer estimates a forfeiture rate. Instead, forfeitures are recognized as they occur. Ampio estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. Expected volatility 95.4% - 113.2 % Risk free interest rate 1.92% - 2.13 % Expected term (years) 5.0 - 6.5 Dividend yield 0.0 % Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses or selling, general and administrative expenses as set forth in the table below. Three Months Ended March 31, 2017 2016 Research and development expenses Stock based compensation $ 42,000 $ 90,000 General and administrative expenses Common stock issued for services 60,000 60,000 Stock based compensation 89,000 520,000 $ 191,000 $ 670,000 Unrecognized expense at March 31, 2017 $ 491,000 Weighted average remaining years to vest 1.95 Warrants In connection with Ampio’s 2016 registered direct offering, Ampio issued to an investor warrants to purchase an aggregate of 5,000,000 1.00 3,112,000 Also in connection with Ampio’s 2016 registered direct offering, Ampio issued to the placement agent warrants to purchase an aggregate of 150,000 0.9375 150,000 Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding December 31, 2016 5,648,576 $ 1.20 4.28 Warrants exercised - $ - Outstanding March 31, 2017 5,648,576 $ 0.67 4.14 In March 2017, the Company modified 498,576 75,000 In March 2017, the Company modified the five million warrants issued in conjunction with the Company’s registered direct offering with an original strike price of $ 1.00 0.40 1.1

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 9—Related Party Transactions Sponsored Research Agreement Ampio entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio’s Director and Chief Scientific Officer, Dr. Bar-Or, in September 2009, which has been amended six times with the last amendment occurring in January 2015. Under the amended terms of the research agreement, Ampio will provide personnel with an equivalent value of at least $ 325,000 725,000 60.5 Service Agreement In July 2015, Ampio entered into an agreement with Aytu whereby Aytu agreed to pay Ampio $ 30,000 18,000 17,000 12,000 39,000 80,000

Litigation

Litigation	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Litigation	Note 10—Litigation As previously disclosed, on May 8, 2015 and May 14, 2015, purported stockholders of the Company brought two putative class action lawsuits in the United States District Court in the Central District of California, Napoli v. Ampio Pharmaceuticals, Inc., et al., Case No. 2:15-cv-03474-TJH and Stein v. Ampio Pharmaceuticals, Inc., et al., Case No. 2:15-cv-03640-TJH (the “Securities Class Actions”), alleging that Ampio and certain of its current and former officers violated federal securities laws by misrepresenting and/or omitting information regarding the STEP study. The cases were consolidated, and on February 8, 2016, the plaintiffs filed a consolidated amended complaint alleging claims under Sections 10(b) and 20(a) and Rule 10b-5 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Sections 11 and 15 under the Securities Act of 1933 on behalf of a putative class of purchasers of common stock from January 13, 2014 through August 21, 2014, including purchasers in the Company’s offering on February 28, 2014. On April 8, 2016, Ampio and the other defendants moved to dismiss the consolidated amended complaint. The Court granted the motion to dismiss, with leave to amend, on August 4, 2016. On September 27, 2016, plaintiffs filed their second amended complaint, alleging the same claims set forth in the consolidated amended complaint during the same class period. The lawsuits seek unspecified damages, pre-judgment and post-judgment interest, and attorneys’ fees and costs. On or about November 8, 2016, the parties reached an agreement in principle on a comprehensive settlement of all claims asserted in the lawsuit with no admission of liability by any defendants and with any settlement amounts being funded by insurance. On or about December 12, 2016, the parties filed a Joint Notice of Settlement with the Court, and on January 31, 2017 plaintiffs filed a motion for preliminary settlement approval and requested a date for a final settlement approval hearing (the “Motion”). On February 8, 2017, the Court denied the Motion but granted plaintiffs leave to file a renewed motion to address class certification issues noted by the Court. On February 28, 2017, plaintiffs filed a renewed motion for preliminary approval with the Court. The Court granted that motion and set a final settlement approval hearing for August 28, 2017. The settlement, which provides for dismissal of all claims with prejudice, is subject to final approval by the Court. Upon final approval by the Court, all claims will be dismissed with prejudice. On August 6, 2015 and September 25, 2015, purported stockholders of the Company brought derivative actions in the United States District Court in the Central District of California, Oglina v. Macaluso et al., Case No. 2:15-cv-05970-TJH-PJW (“Oglina action”) and the Colorado state court in Denver, Loyd v. Giles et al., Case No. 2015CV33429 (“Loyd action”), alleging primarily that the directors and officers of Ampio breached their fiduciary duties because of their alleged misstatements and/or omissions regarding the STEP study. Pursuant to the parties’ stipulation, the United States District Court in the Central District of California has stayed the proceedings in the Oglina action at the present time in accordance with the terms of the parties’ stipulation. Pursuant to the parties’ stipulation, the Colorado state court in Denver has stayed the Loyd action at the present time in accordance with the terms of the parties’ stipulation. On or about March 24, 2017, the parties reached an agreement in principle on a comprehensive settlement of all claims asserted in both the Oglina action and the Loyd action. On or about April 14, 2017, the plaintiffs filed a motion for preliminary settlement approval. The Court granted that motion and set a final settlement approval hearing for June 19, 2017. The settlement, which provides for dismissal of all claims with prejudice, is subject to final approval by the Court. Upon final approval by the Court, all claims will be dismissed with prejudice. The Company believes these shareholder derivative actions are without merit and intends to defend these actions vigorously. The Company currently believes the likelihood of a loss contingency related to these matters is remote and, therefore, no provision for a loss contingency is required.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation –Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting” 18,000 In August 2016, the FASB issued ASU 2016-15 Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, which provides guidance on the presentation of certain cash receipts and cash payments in the statement of cash flows to reduce diversity in existing practice. ASU 2016-15 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted. During fiscal 2016, the Company early adopted this standard with no impact on the quarters ended March 31, 2017 and March 31, 2016 cash flow categorizations. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following: Estimated As of March 31, As of December 31, Useful Lives in years 2017 2016 Manufacturing facility/clean room 8 $ 2,734,000 $ 2,734,000 Leasehold improvements 10 6,075,000 6,075,000 Office furniture and equipment 3 -10 557,000 557,000 Lab equipment 5 -10 1,044,000 1,026,000 Less accumulated depreciation and amortization (2,716,000) (2,412,000) Fixed assets, net $ 7,694,000 $ 7,980,000

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents Ampio’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2017, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total March 31, 2017 ASSETS Trading security Aytu (Note 4) $ 92,000 $ - $ - $ 92,000 LIABILITIES Warrant derivative liability $ - $ - $ 3,112,000 $ 3,112,000 December 31, 2016 ASSETS Trading security Aytu (Note 4) $ 123,000 $ - $ - $ 123,000 LIABILITIES Warrant derivative liability $ - $ - $ 4,239,000 $ 4,239,000
Marketable Securities [Table Text Block]	Value at December 31, Unrealized Fair Value Maturity in Years 2016 Gains Losses 2017 Trading security Aytu (Note 4) Less than 1 year $ 123,000 $ - $ (31,000) $ 92,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy: Derivative Instruments Balance as of December 31, 2016 $ 4,239,000 Change in fair value included in derivative gain (1,127,000) Balance as of March 31, 2017 $ 3,112,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Summary of Commitments and Contingencies	Commitments and contingencies are described below and summarized by the following table: Remaining Total 2017 2018 2019 2020 2021 Thereafter Ampion supply agreement $ 7,650,000 $ 2,550,000 $ 2,550,000 $ 2,550,000 $ - $ - $ - Clinical research and trial obligations 557,000 557,000 - - - - - Facility lease 2,552,000 231,000 316,000 326,000 335,000 345,000 999,000 Sponsored research agreement with related party 695,000 289,000 325,000 81,000 - - - $ 11,454,000 $ 3,627,000 $ 3,191,000 $ 2,957,000 $ 335,000 $ 345,000 $ 999,000
Rent Expense	Rent expense for the respective periods is as follows: Three Months Ended March 31, 2017 2016 Rent expense $ 65,000 $ 73,000

Common Stock (Tables)

Common Stock (Tables)	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Schedule of Sale of Stock by Subsidiary or Equity Method Investee Disclosure	The following table summarizes Ampio’s total sales under the Agreement for the period indicated: Year Ended December 31, 2016 Total shares of common stock sold 163,254 Average price per share $ 0.94 Gross proceeds $ 153,000 Commissions earned by placement agent $ 5,000 Other expenses $ 98,000

Equity Instruments (Tables)

Equity Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Stock Option Activity	Ampio stock option activity is as follows: Weighted Weighted Average Number of Average Remaining Options Exercise Price Contractual Life Outstanding December 31, 2016 7,175,832 $ 3.64 4.99 Granted 585,000 $ 0.85 Exercised - $ - Forfeited - $ - Expired or Cancelled (3,334) $ 3.02 Outstanding March 31, 2017 7,757,498 $ 3.43 5.13 Exercisable at March 31, 2017 6,904,827 $ 3.71 4.58 Available for grant at March 31, 2017 2,467,503
Summary of Stock Options Outstanding and Exercisable	Stock options outstanding at March 31, 2017 are summarized in the table below: Number of Weighted Weighted Average Options Average Remaining Range of Exercise Prices Outstanding Exercise Price Contractual Lives $0.81 - $2.00 2,575,554 $ 1.06 5.22 $2.01 - $5.00 3,111,944 $ 3.06 5.00 $5.01 - $8.93 2,070,000 $ 6.94 5.21 7,757,498 $ 3.43 5.13
Summary of Stock-Based Compensation Expense	The following table summarizes stock-based compensation expense for the three months ended March 31, 2017 and 2016: Three Months Ended March 31, 2017 2016 Research and development expenses Stock based compensation $ 42,000 $ 90,000 General and administrative expenses Common stock issued for services 60,000 60,000 Stock based compensation 89,000 520,000 $ 191,000 $ 670,000 Unrecognized expense at March 31, 2017 $ 491,000 Weighted average remaining years to vest 1.95
Warrants Issued in Conjunction with its Senior Convertible Debentures	The 150,000 Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding December 31, 2016 5,648,576 $ 1.20 4.28 Warrants exercised - $ - Outstanding March 31, 2017 5,648,576 $ 0.67 4.14
Ampio [Member]
Assumptions Used in Computing Fair Value of All Options Granted	Accordingly, Ampio has computed the fair value of all options granted during this quarter, using the following assumptions: Expected volatility 95.4% - 113.2 % Risk free interest rate 1.92% - 2.13 % Expected term (years) 5.0 - 6.5 Dividend yield 0.0 %

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail)	Mar. 31, 2017USD ($)
Accounting Standards Update 2016-09 [Member]
Basis of Presentation and Business [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets	$ 18,000

Going Concern (Details Textual)

Going Concern (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Net Income (Loss) Attributable to Parent	$ (1,904,210)	$ (6,764,789)
Net Cash Provided by (Used in) Operating Activities	(2,621,040)	(4,883,738)
Cash and Cash Equivalents, at Carrying Value	2,256,341	$ 11,114,654	$ 4,894,834
Stockholders' Equity Attributable to Parent	5,000,000
Retained Earnings (Accumulated Deficit)	$ (155,000,939)		$ (153,078,441)

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Less accumulated depreciation and amortization	$ (2,716,000)	$ (2,412,000)
Fixed assets, net	7,693,942	7,980,011
Manufacturing Facility [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 2,734,000	2,734,000
Estimated useful lives	8 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 6,075,000	6,075,000
Estimated useful lives	10 years
Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 557,000	557,000
Office Furniture And Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Office Furniture And Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 1,044,000	$ 1,026,000
Lab Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Lab Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years

Trading Security Aytu BioScie26

Trading Security Aytu BioScience, Inc.- Additional Information (Detail) - Aytu [Member]	Jan. 04, 2016
Investment Disclosure [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	81.50%
Equity Method Investment, Ownership Percentage	8.60%

Fair Value Considerations - Add

Fair Value Considerations - Additional Information (Detail) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Jul. 31, 2016
Available-for-sale Securities, Equity Securities, Current	$ 91,930	$ 122,641
Aytu Bio Science Inc [Member]
Number Of Ownership Shares In Trading Security	102,201	102,201
Available-for-sale Securities, Equity Securities, Current			$ 269,000

Fair Value Considerations - Fin

Fair Value Considerations - Financial Assets and Liabilities (Detail) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
ASSETS
Trading security in Aytu BioScience, Inc.	$ 92,000	$ 123,000
LIABILITIES
Warrant derivative liability	3,112,133	4,238,606
Fair Value, Inputs, Level 1 [Member]
ASSETS
Trading security in Aytu BioScience, Inc.	92,000	123,000
LIABILITIES
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
ASSETS
Trading security in Aytu BioScience, Inc.	0	0
LIABILITIES
Warrant derivative liability	0	0
Fair Value, Inputs, Level 3 [Member]
ASSETS
Trading security in Aytu BioScience, Inc.	0	0
LIABILITIES
Warrant derivative liability	$ 3,112,000	$ 4,239,000

Fair Value Considerations - Ayt

Fair Value Considerations - Aytu’s Closing Stock Price (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Investment in Aytu BioScience, Fair Value	$ 91,930	$ 122,641
Aytu Bio Science Inc [Member]
Investment in Aytu BioScience, Fair Value	92,000	$ 123,000
Investment in Aytu BioScience, Unrealized Gains	0
Investment in Aytu BioScience, Unrealized Losses	$ (31,000)

Fair Value Considerations - Set

Fair Value Considerations - Sets Forth a Reconciliation of Changes (Detail)	3 Months Ended
	Mar. 31, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2016	$ 4,239,000
Change in fair value included in derivative gain	(1,127,000)
Balance as of March 31, 2017	$ 3,112,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 30, 2014
Commitments and Contingencies [Line Items]
Contractual obligation	$ 11,454,000
Equipment lease payments net	$ 325,000	$ 264,000
Newly Leased Office Space and Manufacturing Facility [Member]
Commitments and Contingencies [Line Items]
Non-cancellable operating lease period	125 months
Non-cancellable operating lease initiation date	Dec. 13, 2013
Non-cancellable operating lease effective date	May 1, 2014
Lease initial base rent per month	$ 23,000
Total base rent over the term of the lease	3,300,000
Sponsored Research Agreement With Related Party [Member]
Commitments and Contingencies [Line Items]
Contractual obligation	$ 695,000
Sponsored Research Agreement termination notice period	180 days
Ampion Study Production [Member]
Commitments and Contingencies [Line Items]
Contractual obligation	$ 7,700,000
Other Commitment	$ 557,000

Commitments and Contingencies32

Commitments and Contingencies - Summary of Commitments and Contingencies (Detail)	Mar. 31, 2017USD ($)
Commitment And Contingencies [Line Items]
Total	$ 11,454,000
2,017	3,627,000
2,018	3,191,000
2,019	2,957,000
2,020	335,000
2,021	345,000
Thereafter	999,000
Ampion Supply Agreement [Member]
Commitment And Contingencies [Line Items]
Total	7,650,000
2,017	2,550,000
2,018	2,550,000
2,019	2,550,000
2,020	0
2,021	0
Thereafter	0
Clinical Research and Trial Obligations [Member]
Commitment And Contingencies [Line Items]
Total	557,000
2,017	557,000
2,018	0
2,019	0
2,020	0
2,021	0
Thereafter	0
Sponsored Research Agreement With Related Party [Member]
Commitment And Contingencies [Line Items]
Total	695,000
2,017	289,000
2,018	325,000
2,019	81,000
2,020	0
2,021	0
Thereafter	0
Facility Lease [Member]
Commitment And Contingencies [Line Items]
Total	2,552,000
2,017	231,000
2,018	316,000
2,019	326,000
2,020	335,000
2,021	345,000
Thereafter	$ 999,000

Commitments and Contingencies33

Commitments and Contingencies - Rent Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Commitment And Contingencies [Line Items]
Rent expense	$ 65,000	$ 73,000

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended
	Sep. 30, 2016	Dec. 31, 2013	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Feb. 29, 2016
Components Of Common Stock [Line Items]
Common Stock, shares outstanding			57,242,164		57,179,686
Common Stock, shares authorized			100,000,000		100,000,000
Common Stock, par value			$ 0.0001		$ 0.0001
Preferred Stock, shares authorized			10,000,000		10,000,000
Preferred Stock, par value			$ 0.0001		$ 0.0001
Remaining common stocks and warrants under shelf registration					$ 82,400,000
Maximum aggregate offering price of equity securities						$ 25,000,000
Stock Issued During Period, Shares, New Issues	5,000,000		5,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1
Proceeds from Issuance of Warrants			$ 3,750,000
Combined Purchase Price, Per Share And Warrant			$ 0.75
Issuance Of Warrants Value			$ 4,100,000
Gain (Loss) on Derivative Instruments, Net, Pretax			1,126,473	$ 0
Maximum Amount Authorized Under Shelf Registration			18,600,000
Common Stock [Member]
Components Of Common Stock [Line Items]
Stock Issued During Period, Value, New Issues			$ 5,000,000
Non Employee Directors [Member] | Common Stock [Member]
Components Of Common Stock [Line Items]
Issuance of common stock for services, shares			62,478	18,126
Issuance of common stock for services			$ 60,000	$ 60,000
Shelf Registration [Member]
Components Of Common Stock [Line Items]
Common stock and warrants		$ 100,000,000
Common stock to be sold by directors and management in future public offerings		1,500,000
Registered Direct Placement [Member]
Components Of Common Stock [Line Items]
Proceeds from Issuance of Warrants			$ 3,400,000
Share Based Compensation, Warrants Issued			150,000
Stock Issued During Period, Value, New Issues			$ 5,000,000
Non Cash Charges			4,200,000
Gain (Loss) on Derivative Instruments, Net, Pretax			$ 804,000
Placement Agent [Member]
Components Of Common Stock [Line Items]
Percentage of commission			6.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.9375
Share Based Compensation, Warrants Issued			150,000
Commission Of Gross Offering Proceeds			$ 225,000
Payment of Financing and Stock Issuance Costs			113,000
Warrants and Rights Outstanding			$ 89,000
Agreement [Member]
Components Of Common Stock [Line Items]
Percentage of commission						3.00%

Common Stock - Sales (Detail)

Common Stock - Sales (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Components Of Common Stock [Line Items]
Total shares of common stock sold | shares	163,254
Average price per share | $ / shares	$ 0.94
Gross proceeds	$ 153,000
Commissions earned by placement agent	5,000
Other expenses	$ 98,000

Equity Instruments - Additional

Equity Instruments - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Sep. 30, 2016	Mar. 31, 2017	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option, Granted		585,000
Stock options exercise price		$ 0.85
Stock Issued During Period, Shares, New Issues	5,000,000	5,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1
Fair Value Adjustment of Warrants		$ 3,112,000
Warrant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding		498,576
Minimum [Member] | Waiver and Consent Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.40
Maximum [Member] | Waiver and Consent Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1
Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation, Warrants Issued		150,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.9375
Registered Direct Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation, Warrants Issued		150,000
Share Vesting On Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option, Granted		25,000
Over Three Year Period [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option, Granted		560,000
Ampio March 2010 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance			11,700,000
Modified Outstanding Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 75,000
Modified Outstanding Warrants One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 1,100,000

Equity Instruments - Stock Opti

Equity Instruments - Stock Option Activity (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	585,000
Weighted Average Exercise Price, Granted	$ 0.85
Weighted Average Remaining Years Contractual Life
Weighted Average Remaining Years Contractual Life, Outstaning		4 years 11 months 26 days
Ampio [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	7,175,832
Number of Options, Granted	585,000
Number of Options, Exercised	0
Number of Options, Forfeited	0
Number of Options, Expired or Cancelled	(3,334)
Number of Options, Ending Balance	7,757,498	7,175,832
Number of Options, Exercisable	6,904,827
Number of Options, Available for grant	2,467,503
Weighted Average Exercise Price, Beginning Balance	$ 3.64
Weighted Average Exercise Price, Granted	0.85
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Forfeited	0
Weighted Average Exercise Price, Expired or Cancelled	3.02
Weighted Average Exercise Price, Ending Balance	3.43	$ 3.64
Weighted Average Exercise Price, Exercisable	$ 3.71
Weighted Average Remaining Years Contractual Life
Weighted Average Remaining Years Contractual Life, Outstaning	5 years 1 month 17 days
Weighted Average Remaining Years Contractual Life, Exercisable	4 years 6 months 29 days

Equity Instruments - Summary of

Equity Instruments - Summary of Stock Options Outstanding and Exercisable (Detail)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	7,757,498
Weighted Average Exercise Price	$ 3.43
Expected term (years)	5 years 1 month 17 days
$0.81 - $2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices Lower	$ 0.81
Range of Exercise Prices Upper	$ 2
Number of Options Outstanding | shares	2,575,554
Weighted Average Exercise Price	$ 1.06
Expected term (years)	5 years 2 months 19 days
$2.01 - $5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices Lower	$ 2.01
Range of Exercise Prices Upper	$ 5
Number of Options Outstanding | shares	3,111,944
Weighted Average Exercise Price	$ 3.06
Expected term (years)	5 years
$5.01 - $8.93 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices Lower	$ 5.01
Range of Exercise Prices Upper	$ 8.93
Number of Options Outstanding | shares	2,070,000
Weighted Average Exercise Price	$ 6.94
Expected term (years)	5 years 2 months 16 days

Equity Instruments - Assumption

Equity Instruments - Assumptions Used in Computing Fair Value of All Options Granted (Detail)	3 Months Ended
	Mar. 31, 2017
Expected volatility, Minimum	95.40%
Expected volatility, Maximum	113.20%
Risk free interest rate, Minimum	1.92%
Risk free interest rate, Maximum	2.13%
Dividend yield	0.00%
Maximum [Member]
Expected term (years)	6 years 6 months
Minimum [Member]
Expected term (years)	5 years

Equity Instruments - Summary 40

Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at March 31, 2017	$ 491,000
Weighted average remaining years to vest	1 year 11 months 12 days
Research and Development Expenses [Member] | Stock Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 42,000	$ 90,000
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	191,000	670,000
General and Administrative Expenses [Member] | Stock Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	89,000	520,000
General and Administrative Expenses [Member] | Common Stock Issued for Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 60,000	$ 60,000

Equity Instruments - Warrants I

Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Number of Warrants Outstanding
Number of Warrants Outstanding, Beginning Balance	5,648,576
Number of Warrants Outstanding, Ending Balance	5,648,576	5,648,576
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 1.2
Weighted Average Exercise Price, Outstanding Ending Balance	$ 0.67	$ 1.2
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding	4 years 1 month 20 days	4 years 3 months 11 days
PrivateRegistered Direct Placements [Member]
Number of Warrants Outstanding
Number of Warrants, Exercised	0
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Warrants Exercised	$ 0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended			6 Months Ended
	Jan. 31, 2017	Jul. 31, 2015	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2016	Mar. 30, 2014
Related Party Transaction [Line Items]
Equipment lease payments net			$ 325,000				$ 264,000
Trauma Research LLC [Member] | First Installment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Equipment lease payments net			325,000
Consideration for services related to research and development			$ 725,000
Contract term			60 years 6 months
AytuBioScienceInc [Member]
Related Party Transaction [Line Items]
Shared Overhead Cost	$ 12,000	$ 30,000	$ 39,000	$ 18,000	$ 80,000	$ 17,000

Litigation - Additional Informa

Litigation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017
Number of class action lawsuits	2